TD Cowen Begins Coverage on KalVista Pharmaceuticals (NASDAQ:KALV)

Equities research analysts at TD Cowen initiated coverage on shares of KalVista Pharmaceuticals (NASDAQ:KALV) in a report released on Tuesday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $30.00 price target on the specialty pharmaceutical company’s stock. TD Cowen’s price objective indicates a potential upside of 245.62% from the company’s previous close.

A number of other brokerages have also issued reports on KALV. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Bank of America started coverage on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $25.00.

KalVista Pharmaceuticals Stock Down 3.9 %

Shares of NASDAQ:KALV opened at $8.68 on Tuesday. KalVista Pharmaceuticals has a 52-week low of $7.97 and a 52-week high of $16.88. The stock has a market cap of $428.95 million, a P/E ratio of -2.38 and a beta of 0.86. The business has a fifty day moving average of $9.62 and a two-hundred day moving average of $11.39.

Insider Activity

In related news, insider Paul K. Audhya sold 8,077 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.26, for a total value of $74,793.02. Following the completion of the sale, the insider now owns 94,199 shares in the company, valued at approximately $872,282.74. This trade represents a 7.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Benjamin L. Palleiko sold 7,627 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $9.75, for a total value of $74,363.25. Following the completion of the sale, the chief executive officer now directly owns 274,596 shares in the company, valued at approximately $2,677,311. The trade was a 2.70 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,291 shares of company stock valued at $304,086. Company insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several hedge funds have recently bought and sold shares of KALV. China Universal Asset Management Co. Ltd. grew its position in KalVista Pharmaceuticals by 67.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock valued at $96,000 after acquiring an additional 3,328 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of KalVista Pharmaceuticals in the third quarter valued at approximately $126,000. SG Americas Securities LLC acquired a new position in shares of KalVista Pharmaceuticals in the third quarter valued at approximately $153,000. Quest Partners LLC purchased a new stake in KalVista Pharmaceuticals during the 3rd quarter worth approximately $175,000. Finally, Evoke Wealth LLC acquired a new stake in KalVista Pharmaceuticals during the 2nd quarter worth approximately $181,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).